{"id":927,"date":"2023-11-03T01:38:05","date_gmt":"2023-11-03T01:38:05","guid":{"rendered":"https:\/\/economicherald.net\/?p=927"},"modified":"2023-11-03T01:38:05","modified_gmt":"2023-11-03T01:38:05","slug":"asx-health-stocks-neuren-up-17pc-on-daybue-sales-argenica-40pc-on-alzheimers-data","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=927","title":{"rendered":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data"},"content":{"rendered":"

Neuren\u2019s blockbuster drug DAYBUE generates big sales in Q3
\nArgenica jumps 40pc after releasing preclinical results from Alzheimer\u2019s trial
\nIntegral Diagnostics crashes 30pc after conceding more inflationary pressures ahead<\/p>\n

\u00a0<\/p>\n

Neuren\u2019s DAYBUE almost tripled sales in Q3<\/h2>\n

Market darling Neuren Pharma (ASX:NEU)<\/a><\/strong> surged 17% this morning after reporting that its \u00a0Rett Syndrome drug, DAYBUE<\/strong>, generated net sales in Q3 of US$66.9 million, up from US$23.2 million in Q2.<\/p>\n

The company also guided the market for net sales of DAYBUE in Q4 of between US$80 million and US$87.5 million.<\/p>\n

Neuren reported that 800 patients used DAYBUE as at 30 September, and this surge in initial demand has exceeded pre-launch expectations.<\/p>\n

Around 81% of patients remain on DAYBUE treatment at 4 months, while 80% of lives are now covered by formal reimbursement plans.<\/p>\n

Neuren CEO Jon Pilcher said the launch of DAYBUE has been exceptional, with all metrics exceeding expectations.<\/p>\n

\u201cWe are delighted to see the positive impact [of DAYBUE] in the Rett community.<\/p>\n

\u201cThe first full quarter of sales has achieved an annual run-rate of more than US$250 million. For Neuren, in addition to very significant royalty revenues, this brings into focus the potential sales milestone payments,\u201d he said.<\/p>\n

\u00a0<\/p>\n

Argenica jumps 40pc on Alzheimer\u2019s data<\/h2>\n

Argenica Therapeutics (ASX:AGN)<\/a><\/strong> jumped almost 40% this morning after releasing pre-clinical data from its ARG-007 trial on Alzheimer\u2019s disease<\/strong>.<\/p>\n

Data from two separate studies showed that ARG-007 significantly inhibits the cellular uptake and aggregation of tau protein<\/strong> in two different in vitro Alzheimer\u2019s disease models.<\/p>\n

Results confirmed that ARG-007 has the capacity to significantly reduce the uptake of abnormal tau into brain cells, with a 68% and 49% reduction,<\/strong> thereby potentially limiting the spread of abnormal tau between brain cell.<\/p>\n

The spread of tau protein inside brain cells is thought to be a significant cause of Alzheimer\u2019s disease, and an abnormal tau level is a key hallmark of Alzheimer\u2019s disease progression.<\/p>\n

\u201cThis provides further confirmation that ARG-007 can act on multiple targets and in multiple ways, making it an ideal drug candidate for neurodegenerative conditions such as Alzheimer\u2019s disease,\u201d said Argenica\u2019s CEO, Dr Liz Dallimore.<\/p>\n

\u00a0<\/p>\n

IDX acknowledges more cost pain ahead<\/h2>\n

Meanwhile, Integral Diagnostics (ASX:IDX)<\/a><\/strong> crashed by 30% this morning after conceding that clinical staff shortages, particularly in regional areas, and cost inflation, have continued into FY24.<\/p>\n

The company said it\u2019s responding to these pressures by accelerating productivity and efficiency initiatives.<\/p>\n

Its Australian Q1 revenue growth however was 8.4% higher on pcp, and in New Zealand, IDX achieved a 4.1% NZD increase in revenue vs pcp.<\/p>\n

\u00a0<\/p>\n

Share prices today:<\/h2>\n\n

\ufeff<\/span><\/span>\u00a0
\n<\/span><\/p>\n

The post ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Neuren\u2019s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer\u2019s trial Integral Diagnostics crashes 30pc after conceding [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":928,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-927","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=927\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Neuren\u2019s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer\u2019s trial Integral Diagnostics crashes 30pc after conceding [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=927\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-03T01:38:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data\",\"datePublished\":\"2023-11-03T01:38:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=927#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=927\",\"name\":\"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg\",\"datePublished\":\"2023-11-03T01:38:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=927\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=927#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=927","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald","og_description":"Neuren\u2019s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer\u2019s trial Integral Diagnostics crashes 30pc after conceding [more...]","og_url":"https:\/\/economicherald.net\/?p=927","og_site_name":"Economic Herald","article_published_time":"2023-11-03T01:38:05+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=927#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=927"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data","datePublished":"2023-11-03T01:38:05+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=927"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=927#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=927#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=927","url":"https:\/\/economicherald.net\/?p=927","name":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=927#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=927#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg","datePublished":"2023-11-03T01:38:05+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=927#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=927"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=927#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Neurens-blockbuster-drug-DAYBUE-generates-big-sales-in-Q3-and-Argenica-jumps-40pc-on-Alzheimerss-data.-Picture-Getty-7waBLs.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=927#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer\u2019s data"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=927"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/927\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/928"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}